Multidrug resistance in
cancer cells is often associated with an elevation in the concentration of
glutathione (GSH) and the expression of
gamma-glutamylcysteine synthetase (gamma-GCS), a rate-limiting
enzyme for GSH. We constructed a
hammerhead ribozyme against a gamma-GCS heavy subunit (gamma-GCSh)
mRNA transcript and transfected it to human
colonic cancer cells (HCT8DDP) resistant to
cisplatin (CDDP). The effect of the
ribozyme transfection on the drug resistance of
cancer cells was studied. (a) Transfection of the
ribozyme decreased the GSH level and the efflux of CDDP-GSH adduct, resulting in higher sensitivity of the cells to CDDP. (b) The transfection suppressed the expression of
ATP-binding cassette (ABC) family of transporters such as
MRP1, MRP2, and MDR1, and stimulated the expression of mutant p53. (c) An electrophoretic mobility shift assay showed that mutant p53 suppresses the SP1-DNA binding activity, suggesting that this mutant p53 is functional and it, in turn, suppresses the expression of
ABC transporters. Collectively, transfection of anti-gamma-GCSh
ribozyme reduced the synthesis of GSH and the expression of
ABC transporters, which causes an increase in the sensitivity of
cancer cells to anticancer drugs. Suppression of the SP1-DNA binding activity by p53 may be
a factor of down-regulation of
ABC transporters.